Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Glucose-lowering effects … - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Glucose-lowering effects and mechanisms of the bile acid-sequestering resin sevelamer

Artikel i vetenskaplig tidskrift
Författare A. Bronden
K. Mikkelsen
D. P. Sonne
M. Hansen
C. Vaben
M. N. Gabe
M. Rosenkilde
Valentina Tremaroli
Hao Wu
Fredrik Bäckhed
J. F. Rehfeld
J. J. Holst
T. Vilsboll
F. K. Knop
Publicerad i Diabetes Obesity & Metabolism
Volym 20
Nummer/häfte 7
Sidor 1623-1631
ISSN 1462-8902
Publiceringsår 2018
Publicerad vid Wallenberglaboratoriet
Institutionen för medicin, avdelningen för molekylär och klinisk medicin
Sidor 1623-1631
Språk en
Länkar https://doi.org/10.1111/dom.13272
Ämnesord antidiabetic drug, drug mechanism, GLP-1, glucose metabolism, type 2 diabetes, farnesoid-x-receptor, type-2 diabetes-mellitus, metabolism, binding, colesevelam, insulin, sequestration, release, disease, protein, Endocrinology & Metabolism
Ämneskategorier Endokrinologi och diabetes

Sammanfattning

Aims Sevelamer, a non-absorbable amine-based resin used for treatment of hyperphosphataemia, has been demonstrated to have a marked bile acid-binding potential alongside beneficial effects on lipid and glucose metabolism. The aim of this study was to investigate the glucose-lowering effect and mechanism(s) of sevelamer in patients with type 2 diabetes. Materials and Methods In this double-blinded randomized controlled trial, we randomized 30 patients with type 2 diabetes to sevelamer (n = 20) or placebo (n = 10). Participants were subjected to standardized 4-hour liquid meal tests at baseline and after 7 days of treatment. The main outcome measure was plasma glucagon-like peptide-1 excursions as measured by area under the curve. In addition, blood was sampled for measurements of glucose, lipids, glucose-dependent insulinotropic polypeptide, C-peptide, glucagon, fibroblast growth factor-19, cholecystokinin and bile acids. Assessments of gastric emptying, resting energy expenditure and gut microbiota composition were performed. Results Sevelamer elicited a significant placebo-corrected reduction in plasma glucose with concomitant reduced fibroblast growth factor-19 concentrations, increased de novo synthesis of bile acids, a shift towards a more hydrophilic bile acid pool and increased lipogenesis. No glucagon-like peptide-1-mediated effects on insulin, glucagon or gastric emptying were evident, which points to a limited contribution of this incretin hormone to the glucose-lowering effect of sevelamer. Furthermore, no sevelamer-mediated effects on gut microbiota composition or resting energy expenditure were observed. Conclusions Sevelamer reduced plasma glucose concentrations in patients with type 2 diabetes by mechanisms that seemed to involve decreased intestinal and hepatic bile acid-mediated farnesoid X receptor activation.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?